A Study of ZL-1310 in Subjects With Small Cell Lung Cancer (NCT06179069)
An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Participants With Small Cell Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (38 Sites)
Showing the first 25 of 38 sites.
- City of Hope — Duarte, California
- Yale Cancer Center — New Haven, Connecticut
- Sarah Cannon Research Institute — Sarasota, Florida
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
- Hackensack University Medical Center — Hackensack, New Jersey
- Roswell Park Comprehensive Cancer Center — Buffalo, New York
- Duke University — Durham, North Carolina
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- University of Pittsburgh Hillman Cancer Center — Pittsburgh, Pennsylvania
- Medical University of South Carolina — Charleston, South Carolina
- NEXT Virginia — Fairfax, Virginia
- The First Affiliated Hospital of Anhui Medical University — Hefei, Anhui
- Beijing Cancer Hospital — Beijing, Beijing Municipality
- The First Affiliated Hospital of Xiamen University — Xiamen, Fujian
- Guangdong Provincial People's Hospital — Guangzhou, Guangdong
- Harbin Medical University Cancer Hospital — Harbin, Heilongjiang
- Henan Cancer Hospital — Zhengzhou, Henan
- Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology — Wuhan, Hubei
- Hunan Cancer Hospital — Changsha, Hunan
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School — Nanjing, Jiangsu
- The Second Affiliated Hospital of Nanchang University — Nanchang, Jiangxi
- Jilin Cancer Hospital — Ch’ang-ch’un, Jilin
- Liaoning Cancer Hospital & Institute — Shenyang, Liaoning
- The First Affiliated Hospital of Xi'an Jiaotong University — Xi'an, Shaanxi
- Affiliated Cancer Hospital of Shandong First Medical University — Jinan, Shandong
📞 Contact the Study Coordinator
Phone: (650) 360-1601
Email: Study-ZL-1310-001@zailaboratory.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in SCLC
Explore by condition: All SCLC clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.